Tumor Biology

, Volume 32, Issue 4, pp 697–705 | Cite as

Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas

  • De-shen Wang
  • Dong-sheng Zhang
  • Miao-zhen Qiu
  • Zhi-qiang Wang
  • Hui-yan Luo
  • Feng-hua Wang
  • Yu-hong Li
  • Rui-hua Xu
Research Article


Pancreatic neuroendocrine tumors (PNETs) are uncommon malignancies. The purpose of this study was to identify the prognostic factors of pancreatic neuroendocrine tumors at a single center in China. Clinical data of 27 patients with PNETs treated at the Sun Yat-sen University Cancer Center between January 1995 and December 2010 were retrospectively reviewed. Survival was estimated with the Kaplan–Meier methodology. Twenty-three patients (85.2%) had nonfunctional tumors and four patients (14.8%) had functional tumors. The majority of PNETs located in the body and/or tail of the pancreas in 20 patients (74.1%). All Patients with functional tumors cause syndromes related to hormone overproduction. Anorexia, nausea, vomiting, obstructive jaundice, weight loss, and incidental mass were more common in patients with nonfunctional tumors. The median follow-up time was 40 months. The overall 1-, 2-, and 5-year accumulative survival rates were 91%, 81%, and 81%, respectively. In univariate analysis, factors associating with significantly better survival included macroscopically radical resection of the primary tumor, tumor–node–metastasis (TNM) staging, World Health Organization (WHO) classification, and palliative chemotherapy. Macroscopically radical resection of the primary tumor, TNM staging, WHO classification, and palliative chemotherapy were prognostic variables which may emerge as a practical clinical tool to predict survival.


Neuroendocrine tumors Pancreas Survival Prognostic analysis 



We gratefully thank the staff members in the Department of Medical Oncology at Sun Yat-sen University Cancer Center for their suggestion and assistance.


This work was supported by the National Natural Science Foundation of China grant 30672408, Guangzhou Bureau of Science and Technology grant 2006Z3-E0041, and Sun Yat-sen University 985 Program Initiation Fund (China).


  1. 1.
    Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–81.PubMedCrossRefGoogle Scholar
  2. 2.
    Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. Tnm staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.PubMedCrossRefGoogle Scholar
  6. 6.
    Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13–27.PubMedCrossRefGoogle Scholar
  7. 7.
    Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet cell tumors. Surgery. 1986;99:671.PubMedGoogle Scholar
  8. 8.
    Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2:473–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang SE, Su CH, Kuo YJ, Shyr YM, Li AF, Chen TH, et al. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region. Pancreas. 2011;40:253–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741–51.PubMedCrossRefGoogle Scholar
  12. 12.
    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.PubMedGoogle Scholar
  13. 13.
    Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of who classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.PubMedCrossRefGoogle Scholar
  16. 16.
    Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803.PubMedCrossRefGoogle Scholar
  17. 17.
    Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, et al. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. J Gastrointest Surg. 2010;14:891–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Gao C, Fu X, Pan Y, Li Q. Surgical treatment of pancreatic neuroendocrine tumors: report of 112 cases. Dig Surg. 2010;27:197–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase ii trial of dacarbazine (dtic) in advanced pancreatic islet cell carcinoma. Study of the eastern cooperative oncology group-e6282. Ann Oncol. 2001;12:1139–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase ii study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Saltz L, Lauwers G, Wiseberg J, Kelsen D. A phase ii trial of carboplatin in patients with advanced apud tumors. Cancer. 1993;72:619–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. 1994;55 Suppl 3:64–9.PubMedGoogle Scholar
  28. 28.
    Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group. J Clin Oncol. 2009;27:4656–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • De-shen Wang
    • 1
    • 2
  • Dong-sheng Zhang
    • 1
    • 2
  • Miao-zhen Qiu
    • 1
    • 2
  • Zhi-qiang Wang
    • 1
    • 2
  • Hui-yan Luo
    • 1
    • 2
  • Feng-hua Wang
    • 1
    • 2
  • Yu-hong Li
    • 1
    • 2
  • Rui-hua Xu
    • 1
    • 2
  1. 1.State Key Laboratory of Oncology in South ChinaGuangzhouChina
  2. 2.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouChina

Personalised recommendations